



LAHIVE
&
COCKFIELD
L L P

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahcoc.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DeCONTI, JR.
ANN LAMPORT HAMMITTE
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
JEANNE M. DIGIORGIO
DEBRA J. MILASINCIC, Ph.D.
NICHOLAS P. TRIANO, III
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN

SEAN D. DETWEILER
CYNTHIA L. KANIK, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
RICHA NAND
MICHAEL PHILIPPS *

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
WILLIAM A. SCOFIELD, JR.
PETER C. LAURO *

PATENT AGENTS
PETER S. STECHER

TECHNICAL SPECIALISTS
MARIA LACCOTRIPE ZACHARAKIS, Ph.D. **
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
EUIHOON LEE
LISA M. DIROCCO
JENNIFER K. ROSENFELD
JUDITH STONE-HULSLANDER, Ph.D.
ALLAN TAMESHTIT, Ph.D.
CATHERINE E. McPHERSON
ERIC F. WAGNER, Ph.D.
SHAHID HASANI, Ph.D.
ASHITA DOSHI, Ph.D.
JACOB G. WEINTRAUB

* Admitted in NY only
** Passed the Patent Bar Examination

GAN 1644

PH 5

May 22, 2001

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Patent Application No.: 09/626,731
Title: *HUMANIZED IMMUNOGLOBULIN REACTIVE WITH
B7-2 AND METHODS OF TREATMENT THEREWITH*
Inventor: Man Sung Co et al.
Filed: July 27, 2000
Our Ref. No.: GNN-5315DV2

RECEIVED
JUN 01 2001
TECH CENTER 1600/2900

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Supplemental Information Disclosure Statement;
2. PTO Form 1449; and
3. A copy of one reference (B2) cited in PTO Form 1449; and
4. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any other necessary fees due in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

May 22, 2001
Date

Meg- EW
Megan E. Williams, Esq., Registration No. 43,270

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

Meg- EW
Megan E. Williams, Esq.
Registration No. 43,270
Attorney for Applicants

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 01 2001

TECH CENTER 1600/290



In re the application of: Man Sung Co et al.

Serial No.: 09/626,731

Filed: July 27, 2000

For: *HUMANIZED IMMUNOGLOBULIN REACTIVE
WITH B7-2 AND METHODS OF TREATMENT
THEREWITH*

Attorney Docket No.: GNN-5315DV2

Group Art Unit: 1644

Examiner:

Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

May 22, 2001
Date of Signature and of Mail Deposit

By:

Megan E. Williams, Esq.
Registration No. 43,270
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their attorney are aware of the following patents, publications or other information, which are cited on the attached PTO Form 1449, and in accordance with 37 C.F.R. §1.97 hereby submit these forms for the Examiner's consideration.

The present application is a Divisional Application of U.S. Serial No. 09/249,011, filed February 12, 1999 (Atty. Docket No. GNN-5315). References B1 and B3-B9 listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the Office in the prior application, and, in accordance with 37 C.F.R. §1.98(d), copies of these references are not enclosed herewith, but will be provided

upon request. Reference B2 has not been previously cited by or submitted to the Office and is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 C.F.R. § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP



Megan E. Williams, Esq.
Registration No. 43,270
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: May 22, 2001

AEM/MEW/JKR/alf

